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ABSTRACT  
ANCA associated vasculitis (AAV) comprises three syndromes with systemic vasculitis (Wegener’s granu-
lomatosis (WG), Churg Strauss syndrome (CSS) and microscopic polyangiitis (MPA)), which all involve 
small and medium sized vessels and are associated with antibodies against cytoplasmatic antibodies in 
neutrophils (ANCA). Polyarteritis nodosa (PAN) is included in this review as it also affects medium sized 
vessels, and has many clinical findings in common with the AAV. 
 Since the recognition of ANCA, increasing data have become available on the epidemiology of these 
vasculitidis. WG constitutes half of the AAV and its prevalence has increased from 30/million in the late 
1980’s in the USA to 160/million in this century in northern Europe. The prevalence for the whole group of 
primary systemic vasculitides is now 300/million in Sweden. The annual incidence of WG increased from 
6.0/million to 14/million during the 1990’s in Tromsø, but it is unknown if this is a true increase or the 
result of an increased awareness of the diagnosis. For the whole group of AAV, the annual incidence in 
most more recent studies is relatively constant over time and by geographical location, ranging from 13 to 
21/million. Nonetheless there are interesting differences in the prevalence of specific vasculitis between 
different geographical areas, as well as for sub specificities of ANCA. 
 There seems to be a South-North gradient for WG and PR3-ANCA with high figures reported from 
northern Europe and southern New Zealand. In European studies WG is 90% PR3-ANCA positive. MPA 
which is predominantly MPO-ANCA associated are more frequent in the Mediterranean countries and also 
has an increasing gradient towards east-Asia, as almost all AAV in China and Japan are diagnosed as 
MPA, predominantly MPO-ANCA positive. 
 There are also some ethnic and gender differences. WG is most prevalent among Caucasians in the USA 
and in people with European ancestors in Paris and in New Zealand, less frequent in Africans and Asians. 
Several studies have shown that the highest incidence of WG is in males 60-70 years old. Females are 
younger at onset, and in children WG is most frequent in girls. 
 With better treatment (cyclophosphamide and corticosteroids), the survival of AAV has increased con-
siderably. However disease control is not optimal, as most of the vasculitis present a remitting-relapsing 
course and organ damage is considerable. Hence, we are still looking to improve treatment regimens. 
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The term vasculitis designates a group of now more 
than fifteen different diseases, in which inflammation 
of the wall of blood vessels occurs in veins, arteries 
and/or capillaries. Depending on the size and localisa-
tion of the affected vessels, patients present with more 
or less clinically distinct symptoms. While most types 
of vasculitis were previously considered to be rare, this 
is no longer the case (1). In addition, vasculitides may 
cause severe morbidity and increase mortality due to 
vascular obstruction with tissue ischemia and infarc-
tion of several organ systems (2,3). 
 Within the group of vasculitides, there is a distinct 
subgroup consisting of Microscopic Polyangiitis 
(MPA), Churg Strauss syndrome (CSS) and Wege-
ner’s granulomatosis (WG). These syndromes are all 
characterised by the presence of necrotizing lesions of 
small vessels and the regular presence of antibodies 
against cytoplasmatic antigens in neutrophils (ANCA) 
and therefore nowadays grouped together as ANCA 
associated vasculitis (AAV) (4-6). Polyarteritis nodosa 
(PAN) is not included in this group by most authors 
given its infrequent association with ANCA and its 
known (causal) relationship with viral hepatitis (7). 
However, as PAN affects similar vessels as AAV, 
PAN is often grouped along with the AAV. Increased 
scientific interest has resulted in enhanced manage-
ment and has resulted in better outcomes in AAV over 
the last two decades (2,8). Thus the epidemiology of 





The AAV follow a relapsing-remitting time course and 
account for considerable morbidity and mortality. 
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They affect numerous organs, and are a major cause of 
kidney disease, caused by a necrotizing focal segmen-
tal glomerulonephritis, often leading to end stage renal 
failure, despite the best current treatment strategies. 
The lack of a unifying etiology on the one hand and 
the need for an accurate assessment to guide patient 
management on the other hand, is a constant challenge 
for clinicians involved in patient care. While it is 
essential to exclude infectious and other autoimmune 
diseases that can mimic primary vasculitis, the sub-
sequent classification of the AAV is most often guided 
by classification criteria proposed by the American 
College of Rheumatology (ACR) (9-12) (Table 1). 
These criteria were meant to help identify patients with 
specific vasculitic diagnoses within a large cohort of 
vasculitis patients and were based on expert diagnosis 
(9). Their main aim was to allow observational and 
interventional studies in groups of patients with similar 
disease in different regions. The resulting criteria had 
82-88% sensitivity and 92-99% specificity for PAN (3 
of 10 criteria), WG (2 of 4 criteria) and CSS (4 of 6 
criteria) against the group of other vasculitis patients 
indicating at least 10% false negative and 5-10% false 




Table 1.  American College of Rheumatology classification criteria for Wegener’s granulomatosis (WG), Churg Strauss 
syndrome (CSS) and Polyarteritis nodosa (PAN) (10-12). 
 
Diagnosis  Criterion Definition 
WG 1 Nasal or oral inflammation Development of painful or painless oral ulcers or purulent or bloody nasal 
discharge 
 2 Abnormal chest radiograph Chest radiograph showing the presence of nodules, fixed infiltrates, or cavities 
 3 Urinary sediment Microheamaturia (> 5 red blood cells per high power field) or red cell casts in 
urine 
 4 Granulomatous inflammation 
on biopsy 
Histologic changes showing granulomatous inflammation within the wall of 
an artery or in the perivascular or extravascular area (artery or arteriole) 
    
CSS 1 Asthma History of wheezing or diffuse highpitched rales on expiration.  
 2 Eosinophilia Eosinophilia > 10% on white blood cell differential count.  
 3 Mononeuropathy or 
polyneuropathy  
Development of mononeuropathy, multiple mononeuropathies, or 
polyneuropathy (i.e., glove/stocking distribution) attributable to a systemic 
vasculitis.  
 4 Pulmonary infiltrates,           
non-fixed  
Migratory or transitory pulmonary infiltrates on radiographs (not including 
fixed infiltrates), attributable to a systemic vasculitis.  
 5 Paranasal sinus abnormality  History of acute or chronic paranasal sinus pain or tenderness or radiographic 
opacification of the paranasal sinuses.  
 6 Extravascular eosinophils  Biopsy including artery, arteriole, or venule, showing accumulations of 
eosinophils in extravascular areas.  
    
PAN 1 Weigth loss ≥ 4 kg  Loss of 4 kg or more of body weight since illness began, not due to dieting or 
other factors. 
 2 Livedo reticularis  Mottled reticular pattern over the skin of portions of the extremities or torso. 
 3 Testicular pain or tenderness  Pain or tenderness of the testicles, not due to infection, trauma, or other 
causes. 
 4 Myalgias, weakness, or leg 
tenderness  
Diffuse myalgias (excluding shoulder end hip girdle) or weakness of muscles 
or tenderness of leg muscles 
 5 Mononeuropathy or 
polyneuropathy  
Development of mononeuropathy, multiple neuropathies, or polyneuropathy. 
 6 Diastolic BP >90 mm Hg  Development of hypertension with diastolic blood pressure higher than 90 
mmHg. 
 7 Elevated BUN or creatinine  Elevation of blood urea nitrogen (BUN) >40 mg/dl or creatinine >1.5 mg/dl 
(132µmol/L), not due to dehydration or obstruction. 
 8 Hepatitis B virus  Presence of he patitis B surface antigen or antibody in serum. 
 9 Arteriographic abnormality  Arteriogram showing aneurysms or occlusions of the visceral arteries, not due 
to arteriosclerosis, fibromuscular dysplasia, or other noninflammatory causes. 
 10 Biopsy of small or medium-
sized artery containing poly-
morphnuclear neutrophils  
Histologic changes showing the presence of granulocytes or granulocytes and 
mononuclear leucocytes in the artery wall. 
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 Subsequent refinements to our thinking about vas-
culitis were made by an expert consensus meeting, the 
Chappel Hill Consensus Conference in 1994 that 
aimed to better define the various types of systemic 
vasculitis in order to increase our understanding of 
how various elements may contribute to the specific 
disease manifestations (13) (Table 2). This fundamen-
tally different approach resulted in the description of 
MPA as a separate entity from PAN and also estab-
lished the role for either histological proof or reliable 
surrogate markers of AAV in clinical practice. 
 The detection of ANCA has altered the clinical app-
roach to patients with a possible vasculitic syndrome, 
but is neither incorporated in the ACR criteria nor in 
the CHCC definitions. This has led a group of doctors 
interested in epidemiology of vasculitis to develop a 
stepwise algorithm using both the ACR criteria, the 
CHCC definitions and ANCA result, as a method to 
permit epidemiological comparisons without confoun-
ding by classification (14). This algorithm, called 
EMEA algorithm, also defines the surrogate markers 




The gold standard for a diagnosis of AAV is histologic 
evidence of small vessel vasculitis in the context of a 
clinical constellation with respiratory and renal symp-
toms together with a positive ANCA result (15). Biop-
sy findings include leukocyte invasion of the vessel 
wall, ensuing vessel wall damage and extravasations of 
red blood cells, fibrinoid necrosis, thrombosis, and 
sometimes a granulomatous reaction. Importantly, ne-
gative biopsy findings do no necessarily exclude AAV 
given the potential for skip lesions in vessels (16). 
 The clinical constellation is often that of a patient 
with a (sub)acute presentation of a systemic inflamma-
tory reaction with constitutional symptoms as fever, 
fatigue, tiredness and weight-loss together with more 
specific organ findings such as pulmonary-renal 
syndrome with nasal discharge, cough, dyspnoea and a 
uraemic/nephritic syndrome. Clinical findings in the 
different AAV are depicted in Table 4. Laboratory fin-
dings often reflect the degree of systemic inflamma-
tion with increased levels of acute phase reactants, the 





Table 2.  Chappel Hill Consensus Conference’s definitions of Wegener’s granulomatosis (WG), Microscopic polyangiitis 
(MPA), Churg Strauss syndrome (CSS) and Polyarteritis nodosa (PAN) (13). 
 
Diagnosis Definitions 
WG Granulomatous inflammation involving the respiratory tract, and necrotizing vasculitis affecting small to medium-
sized vessels (e.g. capillaries, venules, arterioles and arteries). Necrotizing glomerulonephritis is common. 
MPA Necrotizing vasculitis, with few or no immune deposits, affecting small vessels (i.e. capillaries, venules or 
arterioles). Necrotizing arteritis affecting small and medium-sized arteries may be present. Necrotizing 
glomerulonephritis is very common. Pulmonary capillaritis often occurs. 
CSS Eosinophil-rich and and granulomatous inflammation involving the respiratory tract, and necrotizing vasculitis 
affecting small to medium-sized vessels, and associated to asthma and eosinophilia. 
PAN Necrotizing inflammation of medium-sized or small arteries without glomerulonephritis or vasculitis in arterioles, 





Table 3.  Surrogate markers for vasculitis in the EMEA algorithm (14). 
 
Surrogate markers for granulomatous disease (Wegener’s granulomatosis)* 
Upper airways Bloody nasal discharge and crusting for >1 month, or nasal ulceration 
 Chronic sinusitis, otitis media or mastoiditis for >3 months 
 Saddle nose deformity/destructive sinonasal disease 
 Retro-orbital mass or inflammation (pseudotumour) 
 Subglottic stenosis 
Lower airways Radiologic evidence of fixed pulmonary infiltrates, nodules or cavitations present for > 1 month 
 Bronchial stenosis 
  
Surrogate markers for renal vasculitis (glomerulonephritis)* 
 Haematuria associated with red cell casts or >10% dysmorphic erythrocytes 
 2+ haematuria and 2+ proteinuria on urinalysis 
* Only one surrogate marker is necessary to support the diagnosis. In all cases other causes must be excluded. 
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specific signs of target organ dysfunction such as low 
levels of oxygenation, increased levels of serumcreati-
nin and the combined presence of hematuria and pro-
teinuria. Ocular, skin and peripheral nerve affection 
are also often present (17,18). The detection of a 
positive result for ANCA by either immunofluores-
cence or ELISA technique in a patient with systemic 
disease has a considerable clinical impact as it is often 
used as a surrogate marker in cases of suspected vas-
culitis (19). Nonetheless, ANCA testing by itself has 
only limited sensitivity and specificity for the diagno-




Incidence and prevalence  
Classic PAN is the oldest of these systemic vasculi-
tides, and was described by Kussmaul and Meyer in 
1866 (21). WG was described in the 1930s, MPA in 
the 1940s and CSS in the 1950s. However, early litera-
ture on the epidemiology of vasculitis has to be inter-
preted carefully as the term “polyarteritis nodosa” was 
used to describe any kind of small to medium sized 
vasculitis until the 1980s. Even though classification 
by the ACR criteria in 1990 was a great improvement 
for epidemiological studies, MPA was still included in 
the PAN diagnosis. As MPA was defined as a separate 
entity from PAN by the CHCC definition in 1994, it is 
important to check which disease criteria or definition 
is used when comparing different epidemiological 
studies. With this in mind, it is possible to look at the 
epidemiology of vasculitis in different time periods 
and different geographic areas. The early data on WG 
from Olmstead County, United States, in the period 
1976-80 gives an annual incidence of 4.0/ million. In a 
study from Leicester, United Kingdom (UK), during 
the 1980s an increase in annual incidence/million from 
0.7 to 2.8 is reported. The increased awareness of sys-
temic vasculitis after ANCA was described in 1985 
(22) may be the explanation for the observed increase 
in incidence of WG, also seen in our study from north 
Norway (23). However, a true increase in incidence 
has not yet been ruled out. Incidences of WG in the 
adult population in various areas and time periods are 
shown in Table 5. 
 More convincing data exist on a true increase in 
prevalence for the AAV which can be explained both 
by earlier recognition of the diseases and with earlier 
and better treatment resulting in increased survival 




WG has the highest annual incidence rate, of about 10 
per million in northern Europe, while the incidence is 
only half of that in southern Europe (Table 5). This has 
led to a theory of a latitude effect on AAV characteris-
tics, which was recently confirmed in the Southern 
hemisphere in a study that found WG to be much more 
prevalent in southern than in northern New Zealand 
(25). MPA, in contrast, has a higher incidence in 
southern Europe, and is also found more common in 
Asia. A recent study from Japan on AAV with renal 
involvement found a high annual incidence of MPA of 
14.8/million, whereas there were no patients with WG 
(26). Most (91%) patients were MPO-ANCA positive, 
while none were PR3-ANCA positive. Similar fin-
dings was seen in Bejing, China, where most patients 
with ANCA related disease had MPO-ANCA (213 
anti-MPO versus 32 anti-PR3) (27). This is in contrast 
to Swedish findings of 35% MPO-ANCA positive and 
59% PR3-ANCA positive in renal involved WG and 
MPA patients (87% of WG patients tested positive for 
PR3-ANCA) (28). 
 A referral hospital in Mexico City has observed a 
tripled incidence of WG over the last seven years (29). 
The Mexican WG patients have similar ANCA pattern 
as seen in northern Europe and in New Zealand with 
80-90% of WG patients being PR3-ANCA positive 
and 10-15% MPO-ANCA positive. For MPA the 
reverse is found, 50-90% are MPO-ANCA positive 




Table 4.  Clinical findings in ANCA associated vasculitis. 
 
Organs involved WG MPA CSS PAN 
ENT +++ + ++ polypi – 
Kidney ++ +++ + +/HT 
Nervous system ++ + +++ +++ 
Lungs ++ noduli +(+) diffuse + transient – 
Eyes ++ + (+) – 
GI-tractus +(+) +(+) ++ +++ 
Heart + (+) ++ – 
Skin ++ ++ ++ ++ 
Muscle/joint ++ ++ ++ ++ 
ANCA PR3 MPO MPO negative 
ENT: ear-nose and throat, GI: gastrointestinal, WG: Wegener’s granulomatosis 
MPA: microscopic polyangiitis, CSS: Churg Strauss syndrome,  
PAN: polyarteritis nodosa, HT: arterial hypertension,  
ANCA: anti neutrphil cytoplasmic antibody, PR3: proteinasis 3, MPO: myeloperoxidasis. 
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India there seems to be a preponderance of WG (54%) 
compared to MPA (18%), however the frequency of 
PR3- and MPO-ANCA are more equal (48% and 43% 
respectively) (31). These findings all indicate latitude 
and east-west related difference both in the frequency 
of various vasculitides, but also in the ANCA pattern 
for different geographic areas. 
 
ANCA and ethnicity  
The reason for the different specificities of ANCA is 
unclear, but genetic variations may be important. It has 
been shown that WG, associated with PR3-ANCA, is 
more prevalent among Caucasian than black Ameri-
cans (32). In New Zealand WG is twice as common 
among people of European ancestry compared to New 
Zealand Maori or Asian, which again has twice the 
prevalence of people identifying themselves as Pacific 
Islanders (25). In a multiethnic urban area in France, 
the prevalence of primary systemic vasculitis (AAV 
and PAN) was twice as high in individuals of 





Table 5.  Incidence of ANCA associated vasculitis and PAN in the adult population. 
 
 Study Study Incidence/mill/year   






   413 000   8.7 
10.3 
  9.7 
  6.8 
  8.9 







WG, CSS, PAN = ACR,  








   371 100   6.0 
  7.5 
14.4 
  9.3 
   ACR (23) 
Lugo. Spain 1988-98    208 271   4.9 11.6 0.9 0.9 
Norwich, UK 1988-98    413 000 10.6   8.4 3.1 0 
Tromsø, Norway 1988-98    371 100 10.5   2.7 0.5 0.5 
WG, CSS = ACR 
MPA, PAN = CHCC 
(87) 
Northern Germany 1998-2002 2 777 275   8.6 
(6.0-12.0) 







Miyazaki, Japan 2000-04    968 950 0 14.8 
Includes 
RLV 
0  WG, CSS = ACR,  MPA= CHCC 
RLV = necrotizing vascular injury 
confined to the kidney. 
All patients had renal involvement   





Table 6.  Prevalence of ANCA associated vasculitis. 
 
 Time of Study Prevalence/mill   







  26 
  32 










  58 
  42 
 
  9 
  0 
 
 7 
  2 
 
  9 
  2 
 CHCC (88) 
Norway, south 1996 
(1-year) 
150 500   53  13 33  ACR (89) 
United Kingdom, 
Norwich  
1997 (pp) 413 000   63    145 WG, CSS, PAN = ACR,  
MPA = CHCC 
(41) 
Norway, north  1998 (pp) 460 000   95     ACR (23) 
France, Paris 2000  
(1-year) 
1 093 500   24 25 11 31   90 WG, CSS, PAN = ACR, 
MPA = CHCC 
(33) 
Sweden, south 2002 (pp) 287 500 129 
    160** 
94 14     31**     299** WG, CSS = ACR, 











  4 
  0 
  0 
 WG, CSS = ACR, 
MPA = CHCC 
(30) 
* Time given for point prevalence (pp) or period prevalence (n-year prevalence). 
** The EMEA algoritm is used to for classification, including ANCA and surrogate markers for granulomatous involvement in respiratory 
tract and for glomerulonephritis (14). 
PSV (primary systemic vasculitides) = AAV + PAN 
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Genetic contributions 
 
Despite uncertainty about its aetiopathogenesis, AAV 
are considered to be autoimmune diseases where a 
genetic inclination to autoimmune reactions can be 
triggered by environmental factors. Although case 
reports have illustrated that familial clustering does 
occur, there have so far been no systemic reporting on 
familial aggregation in AAV (34). Genome-wide 
microarray scanning studies have not been reported, 
although single centre studies have reported on candi-
date genes in AAV. Alpha-1 anti-trypsin (AAT) is a 
physiological inhibitor of proteinase-3 (PR3) which is 
one of the antigens targeted by c-ANCA. Carriage of a 
defective allele in the coding region for AAT at the 
protease inhibitor locus (Pi) was the first reported 
genetic risk factor for the development of anti-PR-3 
positive AAV (35) and may lead to increased PR-3 
expression and increased risk for relapse in WG pa-
tients, while PR-3 gene polymorphism does not seem 
to contribute to PR-3 expression (36). Other associa-
tion studies have found no or only weak associations 
between AAV and polymorphic cytokine, HLA, and 
Fcgamma receptor genes (37). 
 
Age and gender 
 
Mean age at onset of WG is 50 years in most studies 
and was stable over 15 years in our study from nort-
hern Norway (23,33,38,39). However, in Germany, 
age at onset has increased with 15 years from 40-49 
years (1966-1993) to 60 years (1998-2002) (40). MPA 
patients is older at diagnosis compared to WG patients. 
In European studies MPA is diagnosed at 60 years 
(33,38), while in New Zealand and in Japan the MPA 
patients are 70 years at diagnosis (26). There are less 
epidemiological data on CSS and PAN, but mean age 
at onset for CSS is about 50 years, while onset of PAN 
is at age 45-48 years (33,38). 
 In both WG and MPA the age and gender-specific 
incidence rate show increase with age, most obvious in 
males. There is an overall peak in the 65-74 year age 
group in Europe, in the 70-74 year age group of MPA 
and RLV in Japan, and 70-79 year group of WG in 
New Zealand (25,26,30,41). In the study from northern 
Norway we found a clear age-specific incidence top 
only in males (65-74 years). The less prominent peak 
incidence in females occurred at younger age (45-54 
years), and moreover, in the whole cohort of WG 
patients with onset of disease from 10-84 years of age, 
all patients with childhood onset were girls (23). Also 
other studies in children report more WG in girls than 
in boys (42). 
 In the adult population the male to female ratio of 
1.3-1.6 in WG (23,33,38). In studies from Paris and 
Sweden there is an opposite male-female ratio of 0.5-
0.9 in MPA, while the data on PAN and CSS are more 
conflicting, with a male-female ratio of 1.5-0.3 and 
1.7-1.0, respectively (33,38). 
 
Annual and seasonal variations 
 
The etiology of the AAV and PAN is unknown except 
for the association of PAN with Hepatitis B virus 
infection (43). The onset of WG, very often involving 
the upper airways has led to the hypothesis that 
inhaled agents or infections could be triggering factors. 
Some studies have showed a seasonal variation, sup-
porting an infectious etiology (44,45). However there 
are now conflicting results concerning seasonal varia-
tion in onset of AAV (23,32,46,47). Also an annual 
variation in onset has been shown in WG (23), as in 
giant cell arteritis (48), but this phenomenon has to be 




The geographical variations in AAV and the possible 
seasonal and annual variations in onset may reflect 
environmental influence. A number of factors have 
been reported to be associated with the development of 
vasculitis, including various infections, silica, hydro-
carbons, inhaled fumes and particulates, drug, allergy, 
vaccination and farming. 
 
Infections 
Infection has been postulated as the cause of AAV 
vasculitis, for WG, since the first description of the 
disease, yet no proof exists. However, classic PAN is 
closely related to Hepatitis B virus (HBV) and cryo-
globulinaemia to Hepatitis C virus (49,50). A number 
of other viruses have been related to vasculitis. Cyto-
megalovirus has been reported to mimic WG, and 
parvovirus has been associated with WG and PAN 
(31). Also bacteria have been proposed as triggering 
factors for vasculitis, especially is staphylococcus 
aureus associated to disease relapse in WG (51). 
 
Silica 
AAV have been associated with exposure to particu-
late silica, like quartz, granite, sandstone or grain dust. 
The high levels of air pollution and silica dust after the 
earthquake in Kobe, Japan, in 1995, and the subse-
quent increase in MPO-ANCA-associated vasculitis, 
suggested a causal relationship (52). Six case-control 
studies have found significant associations between 
AAV and silica exposure, but with some conflicting 
results for the specific diagnoses of WG and MPA (53-
57). The most recent study from the USA found signi-
ficant association only with higher lifetime exposure to 
silica, and indicated that crop harvesting might imply 
special risk (58). 
 
Farming 
Farming in the year prior to onset of AAV was asso-
ciated with an increased risk of developing WG and 
MPA (OR 2.7 and 6.3 respectively), but not CSS in a 
study from the UK (55). The study could not disting-
uish between crops and livestock, but the association 
appeared to be stronger for livestock. An earlier study 
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from the USA failed to find association between WG 
and farming (46). 
 
Inhaled fumes and hydrocarbons 
A case-control study from the USA reported associa-
tion of inhaled fumes and particulate materials, with 
WG compared to healthy and rheumatic disease 
controls, but not to respiratory disease controls. For 
pesticides there was significant difference also to res-
piratory disease controls (46). Conflicting results exist 
for exposure to metals and welding fumes (54,55), as 
for exposure to occupational hydrocarbons and 
solvents (55,59). 
 
Drugs, allergy, vaccinations 
A large number of drugs have been associated with 
vasculitis, most often hypersensitivity vasculitis, but 
propylthiouracil and hydralazine have also been 
reported in association with AAV. In a review of 250 
MPO-positive systemic vasculitis patients, 30 patients 
with the highest MPO-ANCA titer were examined for 
exposure to hydralazine, propylthiouracil, allopurinol, 
penicillamine or sulphasalazine. Among these high 
titered AAV patients 60% had used one or two of these 
drugs within 9 months prior to onset of disease (60). 
However, a possible association was not confirmed in 
another study of 586 patients treated with propylthio-
uracil, as only one case of vasculitis was found (61). 
 Leukotriene receptor antagonists have been linked 
to onset of CSS in several patients. However, recent 
studies raises some doubt about the relation, as it 
seems that patients experience a flare in their asthma 
requiring intensifying treatment, including leukotriene 
receptor antagonists prior to onset of the vasculitis 
(62,63). 
 Two case-control studies have shown significantly 
more allergy during the last year prior to onset of 
primary systemic vasculitis than in healthy controls. 
This also holds true for the specific diagnosis of WG, 
but with conflicting results for MPA and CSS (55,64). 
Autoimmune reactions, including AAV have been 
reported to follow vaccinations (65), but more data is 






The prognosis for AAV has changed dramatically 
during the last 50 years, most notable for WG. In the 
1950s the mean survival of untreated WG was 5 
months with less than 10% surviving 2 years (66). Af-
ter the introduction of cyclophosphamide and cortico-
steroids as standard treatment, patients now experience 
a one year survival of 93% and a 5-year and 10-year 
survival of 79% and 75% respectively (24). Still the 
mortality risk ratio is 4 compared to the general popu-
lation (67), and 5-10% of WG patients die in active 
disease during the first 3 months after diagnosis (24). 
 The increased mortality risk is associated with 
higher age; a rise of each decade in age increasing the 
risk of death in WG patients with a hazard ratio of 2.18 
(24). This is illustrated with the increased mortality in 
patients aged > 50 years from northern Norway 
(Figure 1) and is confirmed in other studies (68,69). 
Also renal involvement at diagnosis (68), especially 
severe renal impairment in a degree demanding dialy-
sis, is predictor of reduced survival (24). Patients who 
had developed permanent organ damage at diagnosis, 






Figure 1.  Kaplan Meier survival plots for 79 WG patients with a mean follow up of 76 months, from 
northern Norway (unpublished).
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 The 5-year survival rate in MPA is between 45% 
and 75% which is worse than in WG (2,70,71). Patient 
survival in CSS is 60-97% at 5 years (72,73) depen-
ding on the presence at diagnosis of one or more of the 
five factors related to worse outcome: proteinuria > 1 
g/day, creatinine > 1.58 mg/dl, gastrointestinal invol-
vement, cardiomyopathy or neurological involvement 
(74). This five factor score has been shown to predict 
reduced survival also in MPA and PAN, though PAN 
(without HBV) has the best survival of these diagno-
ses, with a 10-year survival rate close to 80% (75). 
 
Relapse  
Up to 90% of patients with AAV go into remission 
during the first 3-6 months of treatment. Most AAV 
however, shows a chronic relapsing course, which 
demands close follow-up and long-term therapy with 
immunosuppressive therapy. 
 The relapse rate is highest in WG, with a cumula-
tive relapse rate of more than 60% depending on time 
of follow-up and the intensity of maintenance 
treatment (18,73). The relapse rate is increased in PR3-
ANCA positive patients (76), and a rise in cANCA or 
PR3-ANCA titer predicts relapse (77). The relapse rate 
in MPA is lower than in WG (78). In a French study 
following patients for more than 7 years, the relapse 
rate in MPA was 35% and in CSS 20%. PAN revealed 
the lowest relapse rate, with 20% in non-HBV associa-
ted PAN and 8% in the HBV associated PAN (75). 
 In WG patients from northern Norway we found 
that less intensive treatment during the first 6 months 
was related to increased risk of relapse. A cumulative 
cyclophosphamide dose of < 10 g, and high dose 
prednisolone (≥ 20mg/day) for less than 2.75 months, 
increased the hazard ratio for relapse with 2.8 and 2.4 
respectively (18). 
 Chronic nasal carriage of staphylococcus aureus is 
found in many patients with WG, and is related to 
increased risk of relapse (79). Adjuvant remission 
maintenance treatment with trimethoprim-sulfametho-
oxazole reduced the relapse rate in one study (76). 
 
Organ damage  
Organ damage occurs early in AAV, best studied in 
WG (24,80). Damage can be studied using the vascu-
litis damage index (VDI) (80). Using the VDI, we 
showed that the increase in damage was 6 times higher 
during the first 6 months after diagnosis compared to 
the next 18 months. This early damage was mainly due 
to disease activity (93%), while treatment related 
damage increased later in the disease course (18). The 
early damage was related to disease activity at onset of 
therapy, and could in our study be reduced by longer 
time on cyclophosphamide during the first 6 months. 
Treatment protocols using pulse cyclophosphamide 
resulted in less late damage compared to treatment 
with daily oral cyclophosphamide (24). 
 Nasal and sinus dysfunction is the most frequent 
damage in WG (61% in our study), hearing loss is seen 
in about a third of WG patients, visual loss in 8-9% 
and saddle nose in 16% (24,81). Peripheral neuropathy 
is frequent (43%), but complaint on pulmonary symp-
toms was only reported by 24% of patients after 5 
years, although 80% of patients had previous lung 
involvement (82). End stage renal disease (ESRD) 
occurs in about 20% of patients with AAV (24,83). 
Reduced renal survival was related to severe renal 
involvement in terms of dialysis dependence at start of 
treatment in our study (24). The relationship between 
ESRD and initial serum creatinine and dialysis depen-
dency was also seen in another Norwegian study (67). 
 
Malignancy  
The increased life expectancy in AAV is due to more 
rapid recognition and aggressive treatment of the dis-
ease. In most patients this will include the use of cyto-
toxic drugs, in particular the use of oral or intravenous 
cyclophosphamide, that exerts its action by forming 
crosslinks between and within DNA strands and ulti-
mately lead to cell death. While most active metabo-
lites are oxidized, a portion is converted into acrolein 
that is a known bladder toxicant. Not surprisingly, 
increased longevity for WG is thus associated with an 
increased risk of late onset cancer, which mainly can 
be attributed to the use of cyclophosphamide (84,85). 
Cancer risk is not increased in patients that never 
receive cyclophosphamide, while high cumulative 
doses of cyclophosphamide put AAV patients at risk 
for hematological, bladder and skin malignancies after 
7-18 years of disease (84). The known carcinogenic 
effects of acrolein on bladder epithelium are mainly a 






With a population prevalence of vasculitides of 300/ 
million, they represent big challenges not only to the 
treating physician, but also to the total health care 
system. Remission rates and survival in AAV have 
increased during the last 50 years, but disease relapses, 
organ damage and late malignancy still represents big 
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